Skip to content

The Patient based Disease Activity Score (PDASII) validation study

The Patient based Disease Activity Score (PDASII) validation study - The PDASII study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON35066
Enrollment
200
Registered
2010-10-07
Start date
2011-10-05
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic joint inflammation Rheumatoid Arthritis

Interventions

During the course of one year, various patient reported measures, such as the Patient-based Disease Activity Score (P-DASII), the modified Rheumatoid Arthritis Disease Activity Index (RADAI-5), the

Sponsors

Universitair Medisch Centrum Sint Radboud
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis RA according to the ACR criteria 2. Patients starting on either their first DMARD or biological therapy

Exclusion criteria

Exclusion criteria: Patients who are unable to complete the questionnaires/PDASII

Design outcomes

Primary

MeasureTime frame
The primary focus of this study is the effect of training on the concurrent criterion validity of the PDASII. Primary outcome of the study will be the mean difference between the PDASII and DAS28 at 6, 9 and 12 months after baseline.

Secondary

MeasureTime frame
Secondary outcomes will be other clinimetric aspects of the PDASII: Validity - face/content; percentage found to be comprehensive and percentage missing elements - construct; convergent correlation analysis with other measures of disease activity and related components of health assessment questionnaires, discriminant correlation analysis with non-related components of health assessment questionnaires measures of disease activity and health state measures - criterion; with joint damage progression over the course of one year Reliability - intraobserver intra-class correlation coefficient Sensitivity to change - standardised response mean - effect size - minimal important difference (ROC + 75th percentile) Feasibility - average time to complete - average cost to complete - percentage positive interpretability - percentage full-completion Acceptance - percentage physicians and patients willing to use patient reported measure for monitoring

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)